{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43","upperLimit":"71","value":"58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Determine the overall survival rate among all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.\n\nClofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Clofarabine"}],"paramType":"NUMBER","populationDescription":"all participants from phase I-II trial who are treated with any of the 4 dose levels of oral clofarabine","reportingStatus":"POSTED","timeFrame":"3 years","title":"All Phase I-II Participants: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}